AMED Infectious Disease Drug Discovery Industry-Academia-Government Liaison Group website is now available.
May 11, 2022
The AMED Collaboration Group for Drug Discovery in Infectious Diseases was established in 2018 to further promote industry-academia-government collaboration in drug discovery research and development in the field of infectious diseases, mainly by the Japan Agency for Medical Research and Development (AMED), academic societies (the Japanese Society of Infectious Diseases, the Japanese Society of Chemotherapy, the Joint Study Committee of Seven Societies for the Promotion of Therapy and Drug Discovery in Infectious Diseases) and pharmaceutical companies (the Pharmaceutical Manufacturers Association of Japan). It was established in September 2018 with the aim of further promoting industry-academia-government collaboration in drug discovery research and development in the field of infectious diseases.
A website introducing the activities of the Liaison Committee is now available, please click on the link below.
AMED Infectious Disease Drug Discovery Industry-Academia-Government Liaison Group
The first edition of the Japanese version of the Priority Pathogen List (PPL) (March 2021), which was created with the participation of members of the Pharmaceutical Manufacturers Association of Japan (PMAJ) as a list of pathogens to be targeted in AMR drug discovery research, has also been released and is expected to become an important list for planning drug resistance measures in Japan. The list is expected to become an important list for planning drug resistance countermeasures in Japan.